WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back of the eye diseases, including the product candidate Iluvien™ for the treatment of Diabetic Macular Edema, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010.
